EPO publishes decision on Sprycel patent invalidation

27-07-2017

EPO publishes decision on Sprycel patent invalidation

Sjo / iStockphoto.com

A European Patent Office (EPO) Board of Appeal has published its decision that invalidated a patent owned by Bristol-Myers Squibb (BMS) which covered a blockbuster anti-cancer drug.


Bristol-Myers Squibb, EPO, European Patent Office, inventive step, patent, invalidation, blockbuster, Sprycel, dasatinib, protein tyrosine kinase

LSIPR